tetano
Editor, Senior Moderator
Adv Clin Exp Med
. 2021 Feb 11.
doi: 10.17219/acem/130606. Online ahead of print.
The clinical value of high-density lipoprotein in the evaluation of new coronavirus pneumonia
Shipeng Huang[SUP] 1 [/SUP], Congyang Zhou[SUP] 1 [/SUP], Zheng Yuan[SUP] 1 [/SUP], Hui Xiao[SUP] 1 [/SUP], Xiaoping Wu[SUP] 1 [/SUP]
Affiliations
Abstract
Background: The new coronavirus pneumonia (NCP, COVID-19) outbreak began in Wuhan in December 2019. The new coronavirus (2019 novel coronavirus (2019-nCoV)) can cause multiple organ damage, mainly to lung tissue, and induce inflammation in the body.
Objectives: To investigate the changes of high-density lipoprotein (HDL) level in patients with COVID-19 and assess its value in the evaluation and prognosis of this disease.
Material and methods: This paper is a cross-sectional retrospective study. Eighty-six severe COVID-19 patients, 132 non-severe COVID-19 patients and 76 healthy individuals (control group) were recruited to measure triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) using enzyme-coupled colorimetry.
Results: The serum HDL-C level in COVID-19 group was 1.02 ?0.28 mmol/L which was significantly lower than in control group (1.52 ?0.55 mmol/L) (p < 0.05). In addition, the serum HDL-C level in severe COVID-19 group was 0.83 ?1.67 mmol/L, which was significantly lower than that in non-severe COVID-19 group (1.15 ?0.27 mmol/L) (p < 0.05).
Conclusions: Changes in HDL levels in patients with COVID-19 can reflect the severity of the disease and have a clinical significance in establishing the prognosis.
Keywords: blood lipids; critical illness; high-density lipoprotein cholesterol; new coronavirus pneumonia.
. 2021 Feb 11.
doi: 10.17219/acem/130606. Online ahead of print.
The clinical value of high-density lipoprotein in the evaluation of new coronavirus pneumonia
Shipeng Huang[SUP] 1 [/SUP], Congyang Zhou[SUP] 1 [/SUP], Zheng Yuan[SUP] 1 [/SUP], Hui Xiao[SUP] 1 [/SUP], Xiaoping Wu[SUP] 1 [/SUP]
Affiliations
- PMID: 33571404
- DOI: 10.17219/acem/130606
Abstract
Background: The new coronavirus pneumonia (NCP, COVID-19) outbreak began in Wuhan in December 2019. The new coronavirus (2019 novel coronavirus (2019-nCoV)) can cause multiple organ damage, mainly to lung tissue, and induce inflammation in the body.
Objectives: To investigate the changes of high-density lipoprotein (HDL) level in patients with COVID-19 and assess its value in the evaluation and prognosis of this disease.
Material and methods: This paper is a cross-sectional retrospective study. Eighty-six severe COVID-19 patients, 132 non-severe COVID-19 patients and 76 healthy individuals (control group) were recruited to measure triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) using enzyme-coupled colorimetry.
Results: The serum HDL-C level in COVID-19 group was 1.02 ?0.28 mmol/L which was significantly lower than in control group (1.52 ?0.55 mmol/L) (p < 0.05). In addition, the serum HDL-C level in severe COVID-19 group was 0.83 ?1.67 mmol/L, which was significantly lower than that in non-severe COVID-19 group (1.15 ?0.27 mmol/L) (p < 0.05).
Conclusions: Changes in HDL levels in patients with COVID-19 can reflect the severity of the disease and have a clinical significance in establishing the prognosis.
Keywords: blood lipids; critical illness; high-density lipoprotein cholesterol; new coronavirus pneumonia.